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Why is this study important?
Alteplase, tissue type plasminogen activator,t-PA has
been the gold standard for fibrinolytic therapy in acute
ischaemic stroke, approved for use by FDA within 3
hours of symptom onset. Tenecteplase, a genetically
engineered mutant tissue plasminogen activator, with
prolonged plasma half life and higher fibrin selectivity,
has emerged as a promising alternative intravenous
alteplase. This article reviews the efficacy and safety of
2 doses of tenecteplase with alteplase as revealed by
the phase 2B trial and attempts to compare their
relative merits. 
Who were the study participants?
Out of the 2678 patients between 2008 and 2011 with
clinical features of stroke, 75 patients, age > 18 years,
were recruitedin this randomized and blinded trial after
screening within 6 hours. Inclusion criteria were set at
NIHSS score > 4 and modified Rankin scale of < 2. Other
baseline characteristics of patients were as follows:
mean age 70 ± 8.2 years, 51 % males, 61 %
hypertensive, 25 % diabetics and 25 % of the patients
were currently smokers. Those with contraindication
to alteplase were excluded. Prior to being enrolled in
the trials patients underwent CT imaging employing
multi detector scanners (16 or 64 slice) and only those
with intracranial occlusion in the anterior cerebral,
middle cerebral or posterior cerebral artery were
included in the study. CT criteria for selection were: a
perfusion lesion 20 % greater than the infarct core and
evidence of associated vessel occlusion on CT
angiography. 
What was the intervention?
Patients were divided randomly into three subgroups
to receive standard dose of alteplase (0.9 mg per
kilogram, the first 10% administered as an initial bolus
and the remainder over a 1-hour period, with a
maximum dose of 90 mg) or to tenecteplase (0.1 mg
per kilogram, administered as a single bolus, with a
maximum dose of 10 mg; or 0.25 mg per kilogram,
administered as a single bolus, with a maximum dose
of 25 mg). Central block randomization was done in
blocks of 15 which allowed blind review after every 15
patients. 
What were the results?
Perfusion-weighted magnetic resonance imaging was
done to assess difference in re perfusion 24 hours after
treatment. NIHSS scale was employed to establish
change in clinical presentation and symptoms before
and after treatment. Other useful indicators of therapy
benefit like vessel recanalisation post 24 hours and
variation in infarct size were duly noted. Modified
Rankin scale was employed to assess recovery and was
hence calculated at the start of the study and repeated
90 days post treatment.
Primary imaging efficacy outcome as assessed by
percentage reperfusion at 24 hours was higher for
Tenecteplase, 79.3±28.8 compared to Alteplase,
55.4±38.7 (p < 0.004). Improvement in NIHSS score
was used to evaluate clinical efficacy and was higher
for Tenecteplase group 8.0±5.5 than Alteplase group
3.0±6.3 (p < 0.001). Infarct growth when analyzed,
attested to better clinical picture with Tenecteplase
with size going from 3 to 2 ml when seen 24 hours
after therapy and then 90 days later and from 14 to 12
ml for the same time interval in Alteplase group (p <
0.01). Secondary clinical efficacy showed a greater
change in modified Rankin scale for tenecteplase than
Alteplase, the improvement being from 32(24 hour) to
27(90 day) and 9 (24 hour) to 10 (90 day) respectively
for the two groups. Results broadly showed that
higher dose of Tenecteplase yielded better results
than lower dose tenecteplase and Alteplase for all
measures of clinical outcomes
What were the conclusions? 
Tenecteplaseuse was associated with better
thrombolytic performance in imaging-selected
stroke patients compared to Alteplase. Greater
reperfusion as exhibited by tenecteplase also
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reflected onto a better clinical picture after
treatment. 
What does this mean for our patients?
Although expensive, it is far more easier to "drip and
ship" tenecteplase patients than alteplase treated
patients. In addition, although not widely
recommended at this time, the idea of using a tissue
based selection therapy for stroke is useful in that it
will eventually avoid unnecessary toxic treatment.
The development of stroke centers in Pakistan,
which will generally be free for service will benefit
from more stringent selection criteria to avoid both
toxicity and cost. Additionally, alteplase is
neurotoxic and promotes apoptosis in tissue
cultures , tenecteplase has not been reported to do
the same. 
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